Earlier Hepatitis C Cure Assessment Shows Promise for High-Risk Populations
核心洞察
Research presented at AASLD (搜索) demonstrates that sustained virological response at 4 weeks (SVR4) after hepatitis C (搜索) treatment completion is highly predictive of cure with 100% sensitivity and 99.2% positive predictive value.
A separate study of 69 people who inject drugs found perfect concordance between SVR4 and SVR12 measurements, supporting earlier cure assessment in this high-risk population.
Updated clinical guidelines now accept SVR4 as an alternative endpoint for uncomplicated cases, potentially reducing loss to follow-up among vulnerable patient populations.
Two new studies provide compelling evidence that hepatitis C virus (搜索) (HCV (搜索)) cure can be reliably assessed just four weeks after treatment completion, potentially transforming care for vulnerable populations at high risk of being lost to follow-up.
Clinical Trial Data Supports Earlier Assessment
Research presented at the American Association for the Study of Liver Disease (搜索) (AASLD (搜索)) Liver Meeting analyzed data from four randomized clinical trials involving Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Marc Bourliere, MD, of Hôpital Saint Joseph (搜索) in Marseilles, France, and colleagues evaluated 1,032 patients across the POLARIS trials to determine the concordance between sustained virological response at 4 weeks (SVR4) and the current standard of 12 weeks (SVR12).
The results demonstrated remarkable accuracy for early assessment. Of 1,001 patients who achieved both SVR4 and SVR12, only eight achieved SVR4 but failed to maintain cure at 12 weeks. Critically, none of the 23 patients who failed to achieve SVR4 went on to be cured at 12 weeks, yielding 100% sensitivity and a negative predictive value of 100%.
"Achieving SVR4 is highly predictive of HCV (搜索) cure," the researchers concluded. "This earlier time point to confirm HCV cure may be particularly important in persons at high risk to be lost to follow-up."
Real-World Validation in High-Risk Population
A complementary study published in Healio focused specifically on people who inject drugs, a population historically underrepresented in clinical trials but at high risk for treatment discontinuation. Claire C. McDonell, a PhD student at University of California, San Francisco, and colleagues analyzed 69 adults from the No One Waits trial who self-reported lifetime injection drug use.
The study population reflected significant socioeconomic challenges, with 97% living below the national poverty line and 83% having injected drugs in the previous year. Despite these risk factors, the concordance between SVR4 and SVR12 was perfect, with both positive and negative predictive values reaching 100%.
"These findings support the use of SVR4 as an alternative clinical endpoint," McDonell and colleagues wrote. "Importantly, our study provides critical insight into the real-world experiences of a population historically underrepresented in data used to guide clinical updates."
Treatment Completion as Alternative Endpoint
The research also explored an even earlier assessment timepoint. RNA viral load measurements at treatment completion showed a positive predictive value for SVR12 of 96.6% and negative predictive value of 100% among people who inject drugs.
"Our results also suggest that HCV RNA (搜索) at treatment completion may be an informative alternative outcome in uncomplicated cases," the researchers noted. However, they acknowledged concerns about potential relapse after treatment completion and patients whose viral load may not completely disappear until immediately after treatment ends.
Updated Clinical Guidelines
The findings align with recent updates to clinical guidelines. The AASLD (搜索) and Infectious Diseases Society of America (搜索) now consider SVR4 an acceptable indicator of cure for people without cirrhosis (搜索) who are receiving direct-acting antivirals (搜索) (DAAs (搜索)) for the first time. The updated measure addresses the significant challenge of loss to follow-up, which can affect study outcomes when missing SVR12 results are classified as treatment failures.
More than 95% of people who complete DAA treatment for hepatitis C (搜索) are cured, making the disease one of the most successfully treatable chronic viral infections. The traditional 24-week assessment from the interferon era was reduced to 12 weeks with DAAs (搜索) due to the rarity of late relapse.
Clinical Implications
The validation of earlier cure assessment could have significant practical implications for hepatitis C (搜索) elimination efforts. Patients who are difficult to retain in care, including those with substance use disorders, unstable housing, or limited healthcare access, could benefit from knowing their cure status sooner.
Treatment failure patterns identified in the POLARIS trials showed higher rates among patients with HCV (搜索) genotype 1, those with prior treatment experience, and those receiving shorter eight-week courses of therapy, providing guidance for clinicians on which patients may require closer monitoring.